Research Roundup: Mushroom Consumption and Lowered Risk
In a clinical trial, patients with gastric cancer who received low-dose olanzapine during chemotherapy experienced improved appetite and weight gain... Read More
Our Impact
Gastric Cancer Foundation improves the lives of people affected by gastric (stomach) cancer by supporting patient education initiatives and innovative research studies to improve treatments and ultimately, find a cure.
Support Research for a Cure
Every contribution to Gastric Cancer Foundation makes a difference. Honor a loved one, make a tribute to someone’s memory, honor a happy occasion by making a meaningful donation.
-
CISCRP Invites Patients and Caregivers to Participate in Gastric Cancer Focus Group
The Center for Information & Study on Clinical Research Participation (CISCRP) is looking for patients and their care partners who... Read More
Foundation Grant Winners Report Progress in Research Aimed at Combating Gastric Cancer
In 2021, the Gastric Cancer Foundation awarded two $100,000 grants to researchers pursuing novel approaches to treating gastric cancer, as... Read More
AGA-Gastric Cancer Foundation Grantee Sam Klempner’s Research Boosts Understanding of Peritoneal Spread
When Samuel J. Klempner, M.D. received the $300,000 Ben Feinstein Memorial Research Scholar Award from the Gastric Cancer Foundation... Read More
Gastric Cancer Registry Completes Major Data Expansion
In 2021, the Gastric Cancer Foundation granted $257,856 to fund an expansion of the Gastric Cancer Registry (GCR) at Stanford... Read More
Dana-Farber Researcher Wins GCF Grant to Probe PARP Inhibition in Gastric Cancer
Could new technology help identify a new role in gastric cancer for a drug that’s been used for the past... Read More
Foundation Awards Two $100,000 Grants to Advance Gastric Cancer Research
The Gastric Cancer Foundation is committed to addressing a key funding gap in research: Very little funding is available to... Read More
Gastric Cancer Foundation Invites Researchers to Apply for Grants to Support Early-Stage Projects
SAN MATEO, Calif., March 30, 2022 The Gastric Cancer Foundation (GCF) has announced the launch of its 2022 grant program.... Read More
Partner with a Navigator to Find the Right Clinical Trial
More than 750 clinical trials of potential new treatments for gastric cancer are now enrolling patients or are planning to... Read More
Foundation Grant Recipients Report Progress in Studies in Epigenetics and Chromosomal Instability
Last year, the Gastric Cancer Foundation awarded two $75,000 grants to researchers probing new targets for treating gastric cancer. Now... Read More-
Gastric Cancer Registry Makes Strides Towards Major Data Expansion
Earlier this year, the Gastric Cancer Foundation committed $257,856 to the Gastric Cancer Registry at Stanford University, which is using... Read More -
Foundation Research Scholar Reports Progress in Project Focused on Peritoneal Spread
When Samuel J. Klempner, M.D. received the $300,000 Ben Feinstein Memorial Research Scholar Award from the Gastric Cancer Foundation and... Read More -
Foundation Awards New Grants to Researchers Pursuing Novel Approaches in Gastric Cancer
The biggest challenge facing researchers who have exciting but unproven ideas for fighting gastric cancer is raising the funds they... Read More 
Nivolumab/Paclitaxel Combo Shows Antitumor Activity in EBV-Related, MSI-H, PD-L1+ Advanced Gastric Cancer
Opdivo combined with paclitaxel showed anti-tumor activity in a phase 1/2 study of gastric cancer patients with a variety of... Read MoreGastric Cancer Registry Team Reports Major Progress in Webinar
In April, Hanlee Ji, MD, associate professor of medicine at Stanford University and principal investigator of the Gastric Cancer Registry,... Read More
Amgen’s Investigational Bemarituzumab Receives Breakthrough Therapy Designation
The FDA granted breakthrough therapy designation to an experimental drug from Amgen for patients with FGFR2b over expressing and HER2-negative... Read More
Investigational Anti-PD-1 Agent Shows Potential for Treatment of Unresectable or Metastatic MSI-H/dMMR Solid Tumors
The novel checkpoint inhibitor HLX10 showed positive safety and efficacy in a phase 2 clinical trial in patients with microsatellite... Read More
Adjuvant Nivolumab Beneficial in Esophageal, GE Junction Cancer
A study found that patients with gastroesophageal junction cancer who were treated with surgery and chemoradiotherapy had significantly longer disease-free... Read More
FDA Approves Nivolumab Plus Chemo for Frontline Advanced Gastric Cancer
The FDA approved the first immunotherapy for the first-line treatment of advanced gastric cancer, Bristol Myers Squibb’s Opdivo in combination... Read More
Heavy Alcohol Use Is Associated With Gastric Cancer
A study in the American Journal of Gastroenterology found an association between heavy alcohol use and an increased risk of... Read More
Monthly Newsletter
We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.